Anti-p53/TP53 antibody

Cat.#: 101756

Size:

Special Price 193.4 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Anti-p53/TP53 antibody
  • Documents
  • Description
    Rabbit monoclonal to p53/TP53
  • Tested applications
    IHC-P, IF, ICC/IF
  • Species reactivity
    Cynomolgus p53 / TP53
  • Alternative names
    bbl antibody; bfy antibody; bhy antibody; FLJ92943 antibody; LFS1 antibody; p44 antibody; p53 antibody; p53 antibody; RP23-56I20.1 antibody; Tp53 antibody; TP53 antibody; Trp53 antibody; TRP53 antibody
  • Immunogen
  • Isotype
    Rabbit IgG
  • Preparation
    This antibody was obtained from a rabbit immunized with purified, recombinant Cynomolgus p53 / TP53 (E3U906; Met1-Asp393).
  • Clonality
    Monoclonal
  • Formulation
    0.2 μm filtered solution in PBS with 5% trehalose
  • Storage instructions
    This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
    Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
  • Applications

    IHC-P: 1-10 μg/mL

    ICC/IF: 10-25 μg/mL

  • Validations

    p53 / TP53 Antibody, Rabbit MAb, Immunohistochemistry

    p53 / TP53 Antibody, Rabbit MAb, Immunohistochemistry

    Immunochemical staining of cynomolgus p53 in human gastric cancer with rabbit monoclonal antibody (5 µg/mL, formalin-fixed paraffin embedded sections).

    p53 / TP53 Antibody, Rabbit MAb, Immunohistochemistry

    p53 / TP53 Antibody, Rabbit MAb, Immunohistochemistry

    Immunochemical staining of cynomolgus p53 in human lung cancer with rabbit monoclonal antibody (5 µg/mL, formalin-fixed paraffin embedded sections).

    p53 / TP53 Antibody, Rabbit MAb, Immunohistochemistry

    p53 / TP53 Antibody, Rabbit MAb, Immunohistochemistry

    Immunofluorescence staining of Cynomolgus p53 in A431 cells. Cells were fixed with 4% PFA, permeabilzed with 0.3% Triton X-100 in PBS, blocked with 10% serum, and incubated with rabbit anti-Cynomolgus p53 monoclonal antibody (15 µg/ml) at 37℃ 1 hour. Then cells were stained with the Alexa Fluor® 488-conjugated Goat Anti-rabbit IgG secondary antibody (green). Positive staining was localized to nucleus.

  • Background
    p53, also known as Tp53, is a DNA-binding protein which belongs to the p53 family. It contains transcription activation, DNA-binding, and oligomerization domains. p53 protein is expressed at low level in normal cells and at a high level in a variety of transformed cell lines, where it's believed to contribute to transformation and malignancy. p53 (TP53) is a transcription factor whose protein levels and post-translational modification state alter in response to cellular stress (such as DNA damage, hypoxia, spindle damage). Activation of p53 begins through a number of mechanisms including phosphorylation by ATM, ATR, Chk1 and MAPKs. MDM2 is a ubiquitn ligase that binds p53 and targets p53 for proteasomal degradation. Phosphorylation, p14ARF and USP7 prevent MDM2-p53 interactions, leading to an increase in stable p53 tetramers in the cytoplasm. Further modifications such as methylation and acetylation lead to an increase in Tp53 binding to gene specific response elements. Tp53 regulates a large number of genes (>100 genes) that control a number of key tumor suppressing functions such as cell cycle arrest, DNA repair, senescence and apoptosis. Whilst the activation of p53 often leads to apoptosis, p53 inactivation facilitates tumor progression. It is postulated to bind to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Defects in TP53 are a cause of esophageal cancer, Li-Fraumeni syndrome, lung cancer and adrenocortical carcinoma.
  • References
    • Bakhrat A, et al. (2010) Drosophila Chk2 and p53 proteins induce stage-specific cell death independently during oogenesis. Apoptosis. 15(12):1425-34.
    • Kurzhals RL, et al. (2011) Chk2 and p53 are haploinsufficient with dependent and independent functions to eliminate cells after telomere loss. PLoS Genet. 7(6):e1002103.
    • Pardi N, et al. (2011) In vivo effects of abolishing the single canonical sumoylation site in the C-terminal region of Drosophila p53. Acta Biol Hung. 62(4):397-412.
    • Wells BS, et al. (2012) Maintenance of imaginal disc plasticity and regenerative potential in Drosophila by p53. Dev Biol. 361(2):263-76.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"